Cromos Pharma, where the patients are

Boehringer Ingelheim

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »

CRF Health eCOA webinar series

Transcelerate Biopharma recognizes CCRC, CPI certification for good clinical practice

Wednesday, January 15, 2014 11:19 AM

The Association of Clinical Research Professionals (ACRP) has learned that TransCelerate Biopharma now recognizes certification through the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) programs of ACRP's affiliate, the Academy of Clinical Research Professionals, as evidence of Good Clinical Practice (GCP) training.

More... »


Aeterna Zentaris appoints Richard Sachse chief scientific officer

Friday, January 3, 2014 09:51 AM

Aeterna Zentaris, a specialty biopharmaceutical company, has appointed Richard Sachse, M.D., Ph.D., senior vice president, chief scientific officer. Before joining Aeterna Zentaris, Sachse was vice president, head of Global Translational Medicine at Boehringer Ingelheim.

More... »

ideaPoint launches multi-sponsor portal

Thursday, January 2, 2014 10:35 AM

ideaPoint, a provider of partnering and collaboration systems for global enterprises, has announced the availability of a new portal providing a secure system for researchers to request access to anonymized, patient-level clinical trial data provided by sponsors (clinicalstudydatarequest.com). Study sponsors who have committed to provide data through the site currently include Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi and ViiV Healthcare.

More... »

Boehringer Ingelheim planning two global trials of Pradaxa

Tuesday, November 26, 2013 10:34 AM

Boehringer Ingelheim Pharmaceuticals plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI (Randomized Evaluation of Dual Therapy with Dabigatran v. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting), is designed to evaluate the efficacy and safety of PRADAXA in patients with non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stent placement. The second of the new trials, RE-SPECT ESUS(TM) (Randomized Evaluation in Secondary stroke Prevention Comparing the Thrombin inhibitor dabigatran etexilate v. ASA in Embolic Stroke of Undetermined Source), is designed to evaluate the efficacy and safety of PRADAXA as a secondary stroke prevention therapy in patients who have suffered an embolic stroke of undetermined source (ESUS). Embolic strokes occur when a blood clot forms somewhere in the body and travels through the bloodstream to the brain.

More... »

Healthcare Leadership Council profiles inVentiv Health

Tuesday, November 26, 2013 10:00 AM

inVentiv Health, a global provider of best-in-class clinical, commercial and consulting services, has announced a cutting-edge inVentiv program for managing the care of chronic kidney disease has been included in a compilation of breakthrough innovations helping transform the American healthcare system.

More... »

Reinforced safety profile of Boehringer Ingelheim’s Pradaxa released

Tuesday, November 19, 2013 01:37 PM

Boehringer Ingelheim Pharmaceuticals has announced results from a new, long-term, combined analysis of the pivotal phase III RE-LY trial and its extension safety study RELY-ABLE. The data showed that after a median follow up of 4.6 years, with some patients followed up to 6.7 years, rates of stroke/systemic embolism and major bleeding were consistent with rates in previously reported analyses of RE-LY, one of the largest stroke prevention clinical studies ever conducted in patients with non-valvular atrial fibrillation (NVAF).

More... »

Evotec receives $5.4 million milestone payment from Boehringer Ingelheim

Monday, October 21, 2013 11:52 AM

Evotec’s research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of $5.4 million to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

More... »

Evotec receives preclinical milestone payment from Boehringer Ingelheim

Monday, October 14, 2013 09:30 AM

Evotec’s research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of $5.4 million to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

More... »

Ben Venue Laboratories to cease production, cut all 1,100 jobs

Monday, October 7, 2013 01:33 PM

Ben Venue Laboratories, a Bedford, Ohio-based subsidiary of Boehringer Ingelheim that produces sterile injectables, has announced it will cease production by the end of 2013. Despite the ongoing support of the FDA, dedicated employees and investments in facility upgrades, the company cannot return to sustainable production.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs